FDA Issues Complete Response Letter for Etripamil for PSVT
Provided By GlobeNewswire
Last update: Mar 28, 2025
CRL focused on CMC; no clinical issues relating to etripamil raised
$69.7M in cash, cash equivalents and short-term investments as of December 31, 2024
Read more at globenewswire.com
